Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (6): 625-630.doi: 10.3969/j.issn.1000-6621.2021.06.018
• Review Articles • Previous Articles Next Articles
WANG Yuan-zhi, LIANG Zheng-min, QU Meng-jin, ZHOU Xiang-mei()
Received:
2021-01-26
Online:
2021-06-10
Published:
2021-06-02
Contact:
ZHOU Xiang-mei
E-mail:zhouxm@cau.edu.cn
WANG Yuan-zhi, LIANG Zheng-min, QU Meng-jin, ZHOU Xiang-mei. Research progress of tuberculosis vaccine and vaccination strategy[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 625-630. doi: 10.3969/j.issn.1000-6621.2021.06.018
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.06.018
类别 | 抗原 | 佐剂/载体 | 佐剂/载体说明 | 临床阶段 |
---|---|---|---|---|
添加佐剂的亚单位疫苗 | ||||
M72 | Rv1196+Rv0125 | AS01 | 脂质体,TLR4受体激动剂 | Ⅱb |
H56 | ESAT-6+Ag85B+Rv2660c | IC31 | 抗菌肽KLK+寡脱氧核苷酸ODN1a,TLR9受体激动剂 | Ⅱb |
ID93 | Rv2608+Rv3619+Rv3620+Rv1813 | GLA-SE | 溶于水包油角鲨烯乳剂中的吡喃葡萄糖脂,TLR4受体激动剂 | Ⅱa |
GamTBvac | Ag85A+ESAT6-CFP10 | CpG ODN | 寡脱氧核苷酸,TLR9受体激动剂 | Ⅱa |
AEC/BC02 | Ag85B+ESAT6+CFP10 | CpG | 基于CpG和铝盐的新型佐剂BC02 | Ⅰ |
重组病毒载体疫苗 | ||||
TB/Flu-04L | Ag85A+ESAT6 | Flu-04L | 减毒复制缺陷流感病毒(H1N1) | Ⅱa |
AERAS-402 | Ag85A+Ag85B+TB10.4 | rAd35 | 重组复制缺陷人腺病毒载体-35 | Ⅱa |
Ad5Ag85A | Ag85A | Ad5 | 重组复制缺陷人腺病毒载体-5 | Ⅰ |
ChAdOx185A+MVA85A boost | Ag85A | ChAdOx1、MVA | 黑猩猩腺病毒、改良安卡拉牛痘病毒 | Ⅰ |
[1] |
Peck M, Gacic-Dobo M, Diallo MS, et al. Global Routine Vaccination Coverage, 2018. MMWR Morb Mortal Wkly Rep, 2019,68(42):937-942. doi: 10.15585/mmwr.mm6842a1.
doi: 10.15585/mmwr.mm6842a1 URL |
[2] | World Health Organization. Summary of the WHO Position Paper on BCG vaccines: WHO position paper. Geneva:World Health Organization, 2018. |
[3] |
郭倩, 申晨, 申阿东. 干细胞与结核分枝杆菌交互作用的研究进展. 中国防痨杂志, 2021,43(2):186-189. doi: 10.3969/j.issn.1000-6621.2021.02.015.
doi: 10.3969/j.issn.1000-6621.2021.02.015 |
[4] | World Health Organization. The global plan to end TB 2016-2020:the paradigm shift.Geneva:Stop TB Partnership, United Nations Office for Project Services, 2015. |
[5] |
陈柠, 孙琳, 申阿东, 等. 卡介苗接种后发生感染的可能原因研究现况. 中国防痨杂志, 2020,42(8):869-873. doi: 10.3969/j.issn.1000-6621.2020.08.017.
doi: 10.3969/j.issn.1000-6621.2020.08.017 |
[6] |
Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant Bacille Calmette-Guérin vaccine VPM1002:ready for clinical efficacy testing. Front Immunol, 2017,8:1147. doi: 10.3389/fimmu.2017.01147.
doi: 10.3389/fimmu.2017.01147 pmid: 28974949 |
[7] |
Gonzalo AJ, Marinova D, Martin C, et al. MTBVAC:attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Front Immunol, 2017,8:1803. doi: 10.3389/fimmu.2017.01803.
doi: 10.3389/fimmu.2017.01803 URL |
[8] |
Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never treated tuberculosis patients: a meta-analysis. PLoS One, 2011,6(9):e23826. doi: 10.1371/journal.pone.0023826.
doi: 10.1371/journal.pone.0023826 URL |
[9] |
Saqib M, Khatri R, Singh B, et al. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis (Edinb), 2016,101:164-173. doi: 10.1016/j.tube.2016.10.002.
doi: S1472-9792(16)30239-6 pmid: 27865389 |
[10] |
Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine, 2020,38(46):7239-7245. doi: 10.1016/j.vaccine.2020.09.055.
doi: 10.1016/j.vaccine.2020.09.055 URL |
[11] |
Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine, 2010,28(4):1106-1116. doi: 10.1016/j.vaccine.2009.09.134.
doi: 10.1016/j.vaccine.2009.09.134 pmid: 19853680 |
[12] |
Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol, 2017,24(2):e00439-16. doi: 10.1128/CVI.00439-16.
doi: 10.1128/CVI.00439-16 |
[13] |
Tameris M, Mearns H, Penn-Nicholson A, et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med, 2019,7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6.
doi: 10.1016/S2213-2600(19)30251-6 URL |
[14] |
方刚, 顾小燕, 尹小芳. 母牛分枝杆菌菌苗辅助抗结核方案治疗肺结核对患者免疫功能及疾病转归的影响. 中国临床研究, 2020,33(4):501-504. doi: 10.13429/j.cnki.cjcr.2020.04.017.
doi: 10.13429/j.cnki.cjcr.2020.04.017 |
[15] |
Nell AS, D’Lom E, Bouic P, et al. Safety,tolerability,and immunogenicity of the novel antituberculous vaccine RUTI:randomized,placebocontrolled phase Ⅱ clinical trial in patients with latent tuberculosis infection. PLoS One, 2014,9:e89612. doi: 10.1371/journal.pone.0089612.
doi: 10.1371/journal.pone.0089612 URL |
[16] |
Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019,381(25):2429-2439. doi: 10.1056/NEJMoa1909953.
doi: 10.1056/NEJMoa1909953 URL |
[17] |
Coppola M, van Meijgaarden KE, Franken KL, et al. New genomewide algorithm identifies novel in-vivo expressed Mycobacterium tuberculosis antigens inducing human T-cell responses with classical and unconventional cytokine profiles. Sci Rep, 2016,6:37793. doi: 10.1038/srep37793.
doi: 10.1038/srep37793 URL |
[18] | 李菲. 结核潜伏抗原筛选与治疗性融合蛋白疫苗的制备. 兰州: 兰州大学, 2016. |
[19] | 寇一鸣. 结核分枝杆菌新型疫苗的构建及免疫学评价. 长春: 吉林大学, 2018. |
[20] |
Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020,577(7788):95-102. doi: 10.1038/s41586-019-1817-8.
doi: 10.1038/s41586-019-1817-8 URL |
[21] |
Fourie PB, Germishuizen WA, Wong YL, et al. Spray drying TB vaccines for pulmonary administration. Expert Opin Biol Ther, 2008,8(7):857-863. doi: 10.1517/14712598.8.7.857.
doi: 10.1517/14712598.8.7.857 pmid: 18564902 |
[22] |
Manjaly Thomas ZR, Satti I, Marshall JL, et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: a phase I randomised controlled trial. PLoS Med, 2019,16(4):e1002790. doi: 10.1371/journal.pmed.1002790.
doi: 10.1371/journal.pmed.1002790 URL |
[23] |
Manjaly Thomas ZR, McShane H, Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg, 2015,109(3):175-181. doi: 10.1093/trstmh/tru206.
doi: 10.1093/trstmh/tru206 URL |
[24] |
徐菀佚, 乔建斌, 马波, 等. 冻融-冻干法制备的流感疫苗脂质体的细胞免疫研究. 中国药科大学学报, 2015,46(6):730-733. doi: 10.11665/j.issn.1000-5048.20150616.
doi: 10.11665/j.issn.1000-5048.20150616 |
[25] |
赵祥月, 范宇超, 谢青昕, 等. 狂犬病疫苗脂质体冻干粉的免疫原性评价. 中国生物制品学杂志, 2020,33(3):250-253. doi: 10.13200/j.cnki.cjb.003001.
doi: 10.13200/j.cnki.cjb.003001 |
[26] |
Aneesh T, Pall TI, Signe TS, et al. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. Vaccine, 2018,36(23):331-3339. doi: 10.1016/j.vaccine.2018.04.055.
doi: 10.1016/j.vaccine.2018.04.055 URL |
[27] |
Cosgrove CA, Castello-Branco LR, Hussell T, et al. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun, 2006,74(4):2449-2452. doi: 10.1128/IAI.74.4.2449-2452.2006.
doi: 10.1128/IAI.74.4.2449-2452.2006 URL |
[28] |
Hoft DF, Xia M, Zhang GL, et al. PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures. Mucosal Immunol, 2018,11(2):486-495. doi: 10.1038/mi.2017.67.
doi: 10.1038/mi.2017.67 pmid: 28853442 |
[29] |
Magalhaes I, Sizemore DR, Ahmed RK, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One, 2008,3(11):e3790. doi: 10.1371/journal.pone.0003790.
doi: 10.1371/journal.pone.0003790 URL |
[30] |
Cai H, Yu DH, Hu XD, et al. A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol, 2006,25(8):438-447. doi: 10.1089/dna.2006.25.438.
doi: 10.1089/dna.2006.25.438 pmid: 16907641 |
[31] |
Wang QM, Sun SH, Hu ZL, et al. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine, 2004,22(27/28):3622-3627. doi: 10.1016/j.vaccine.2004.03.029.
doi: 10.1016/j.vaccine.2004.03.029 URL |
[32] |
武亚琦. 成人结核病预防策略的探索性研究. 武汉: 华中科技大学, 2019. doi: 10.27157/d.cnki.ghzku.2019.005095.
doi: 10.27157/d.cnki.ghzku.2019.005095 |
[33] |
Andersen P, Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun, 2000,68(2):621-629. doi: 10.1128/iai.68.2.621-629.2000.
doi: 10.1128/iai.68.2.621-629.2000 pmid: 10639425 |
[34] |
Bai C, He J, Niu H, et al. Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells. Tuberculosis (Edinb), 2018,110:104-111. doi: 10.1016/j.tube.2018.04.006.
doi: 10.1016/j.tube.2018.04.006 URL |
[35] |
Kaveh DA, Garcia-Pelayo MC, Hogarth PJ. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine, 2014,32(51):6911-6918. doi: 10.1016/j.vaccine.2014.10.041.
doi: 10.1016/j.vaccine.2014.10.041 URL |
[1] | . Guideline for clinical management of adverse reactions of bacillus Calmette-Guérin [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 532-538. |
[2] | HONG Piao-ru, JIANG Hui-fang, TAO Die-hong, SU Chuan-yong, GUO Shu-ping, WU Hai-ying, JIANG Yu-xia, YE Ying-yan. A case of T-cell large granular lymphocyte leukemia complicated with Mycobacterium avium meningitis together with literature review [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 631-635. |
[3] | LIU Hai-ting, LU Yu. Progress in pharmacodynamic screening of anti-tuberculosis drug combination [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 404-408. |
[4] | LIU Xin, GUO Le, WU Qian-hong. A case of severe myelosuppression caused by anti-tuberculosis drugs and literature review on this issue [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 413-418. |
[5] | Chinese Antituberculosis Association. Tuberculosis research progress in 2020 [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 6-11. |
[6] | YANG Min, FU Liang, DENG Guo-fang. Progress in the treatment and management of tuberculosis complicated with diabetes [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 87-90. |
[7] | LI Guo, PANG Xian-qiong, XU Hua, JING Ming-yan, FAN Pang-shuang, CHEN Shao-ping. Progress in diagnosis and treatment of latent tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 91-95. |
[8] | ZHAO Ai-hua, KANG Wan-li, WANG Guo-zhi, GAO Zheng-lun, DU Wei-xin, LU Jin-biao, SHEN Xiao-bing, SU Cheng, XU Miao, ZHENG Su-hua. Screening for latent tuberculosis infection and identification of BCG vaccination by recombinant Mycobacterium tuberculosis 11 kDa [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 821-825. |
[9] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[10] | CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Possible causes of infection after BCG vaccination [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 869-873. |
[11] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[12] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[13] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[14] | JIANG Li, ZHANG Xiao-qiang, LIU Ling-li, WANG Han, LIU Feng, LI Zhi-yue, SHEN Sheng-rong. Research progress of clinical characteristics of malnourished patients with tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 741-746. |
[15] | FU Liang, DENG Guo-fang. Review on the progress of laboratory tests for activity judgment of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 626-629. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||